RANI (Rani Therapeutics Holdings) Short Percentage of Float


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.75
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RANI vs CGTX, INO, ALDX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Rani Therapeutics Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rani Therapeutics Holdings Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's Short Percentage of Float falls into.


RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price